Cargando…
Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients
BACKGROUND: The rapid course of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic calls for fast implementation of clinical trials to assess the effects of new treatment and prophylactic interventions. Building trial platforms embedded in existing data infrastructures is an i...
Autores principales: | Kusejko, Katharina, Chammartin, Frédérique, Smith, Daniel, Odermatt, Marc, Schuhmacher, Julian, Koller, Michael, Günthard, Huldrych F., Briel, Matthias, Bucher, Heiner C., Speich, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330973/ https://www.ncbi.nlm.nih.gov/pubmed/35902817 http://dx.doi.org/10.1186/s12879-022-07621-x |
Ejemplares similares
-
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
por: Griessbach, Alexandra, et al.
Publicado: (2023) -
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
por: Griessbach, Alexandra, et al.
Publicado: (2023) -
A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®
por: Speich, Benjamin, et al.
Publicado: (2021) -
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2022) -
Are coveralls required as personal protective equipment during the management of COVID-19 patients?
por: Jung, Jongtak, et al.
Publicado: (2021)